MedTrace Logo

Behavioral Pharmacology of Orally Administered THC and D-limonene

NCT06378957 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-05-16

No results posted yet for this study

Summary

The current clinical trial will investigate the effects of orally administered d-limonene (limonene), delta-9-tetrahydrocannabinol (THC) and the combination in healthy adult volunteers.

Conditions

  • Subjective Drug Effects
  • THC
  • D-limonene

Interventions

DRUG

D-Limonene

Oral Limonene administered via capsule

DRUG

Delta-9-THC

Oral delta-9-THC in ethanol vehicle administered via capsule

DRUG

Placebo

Placebo (cellulose) administered via capsule

Sponsors & Collaborators

Principal Investigators

  • Austin Zamarripa, PhD · Johns Hopkins School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-14
Primary Completion
2027-07-01
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06378957 on ClinicalTrials.gov